44 results about "Catenin Proteins" patented technology

The present invention provides a kind of radix schizonepetae extract for treating ulcerative colitis and its preparation method and application, and relates to the field of biomedicine technology. The preparation method of the radix schizonepetae extract of the present invention comprises: soaking radix schizonepetae in water, heating and boiling, condensing and refluxing, filtering, and collecting the filtrate, which is the radix schizonepetae extract. The radix schizonepetae extract of the present invention can reduce collagen deposition and intestinal epithelial cell apoptosis in the colon epithelium of ulcerative colitis, has the effect of downregulating the abnormally high expression of genes and proteins such as N-cadherin, IntegrinA1, Vinculin, TGF-β2, Srcin, etc. in the colon tissue of ulcerative colitis, reduces colon fibrosis and inflammatory damage, protects the barrier function of the colon epithelium, and has the effect of inhibiting the overexpression of Wnt 5A / B and β-Catenin proteins caused by DSS, and alleviates colon fibrosis, thereby achieving the effect of treating ulcerative colitis and alleviating colon fibrosis.

This invention relates to the cosmetic use of a composition for improving gray hair. The composition of this invention promotes melanin synthesis in hair by activating the Wnt / β-catenin signaling pathway, thereby exhibiting significant and excellent effects in inhibiting, preventing, improving, alleviating, delaying, or treating gray hair (white hair syndrome).

The present invention relates to a peptide having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptide of the present invention has an activity of promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating a cell proliferation-related signal protein in human dermal papilla cells, activating β-catenin, improving expression levels of factors downstream of β-catenin, down-regulating expression levels of hair-loss protein DKK-1, and increasing expression of keratins in hair outer root sheath cells (HORSC).

Provided are compounds of the Formula I: (I), or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.

The invention relates to β-catenin-binding peptides and peptidomimetics comprising an amino acid sequence ESILDEHXQRVW or EYPESILDEHXQRVWR, wherein X is L, M, I, F, Y, W or C, or a variant of said amino acid sequences, and to uses thereof.

The invention relates to the technical field of biological medicines, and particularly provides a hair follicle regeneration nano activator as well as a preparation method and application thereof. The activator comprises a first coupling monomer and a second coupling monomer, an oligonucleotide sequence of the first coupling monomer and an oligonucleotide sequence of the second coupling monomer are at least partially complementary and form a double-chain structure through base pairing, the first coupling monomer is formed by coupling a first polypeptide and a first ssDNA, and the second coupling monomer is formed by coupling a second polypeptide and a second ssDNA. The second coupling monomer is formed by coupling a second polypeptide and a second ssDNA; wherein the first polypeptide and the second polypeptide are both specifically targeted to beta-catenin protein. The polypeptide-DNA-polypeptide dimer has a polypeptide-DNA-polypeptide sandwich-type dimer structure, can be specifically combined with beta-catenin in stem cells, only regulates and controls a Wnt / beta-catenin pathway, does not generate non-specific influence on other pathways, and can efficiently activate a hair follicle regeneration related signal pathway and promote a hair follicle development biological process.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The present application provides, in some aspects, methods of determining a beta-catenin depot and uses thereof, for example, to identify compounds that modulate, such as increase, a beta-catenin depot in a cell. Also provided herein, in other aspects, are related methods, such as methods of identifying compounds for the treatment of beta-catenin associated diseases, kits, and useful compounds identified thereby.

The present invention relates to a composition for preventing hair loss or promoting hair growth, containing an ingredient for promoting hair growth or delaying hair loss. In order to confirm this, the wnt / beta-catenin signaling pathway activity promoting effect, the hair papilla cell proliferation effect, and the beta-catenin protein expression amount increasing effect wnt / beta-catenin signaling pathway activity promoting effect, the hair papilla cell proliferation effect and the beta-catenin protein expression amount increasing effect have been confirmed by in vitro experiments. Further, it is confirmed that a good result is exhibited in a researcher evaluation by clinical photograph shooting and an evaluation by hair image shooting after use, thereby exhibiting a high effect of preventing hair loss and / or hair growth. In view of these comprehensive results, the composition of the present invention has excellent effects of preventing hair loss and / or promoting hair growth.

The present invention relates to a composition for inhibiting white hair having an excellent effect of inhibiting the generation of white hair and use thereof. The composition for inhibiting white hair of the present invention has an excellent effect of inhibiting, preventing, ameliorating, alleviating, delaying or treating white hair (poliosis) by promoting the synthesis of melanin in hair through the activation of the Wnt / β-catenin signaling pathway.

The present invention relates to a pharmaceutical composition comprising an aryl piperidine derivative compound or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tankyrase-related cancer diseases. The pharmaceutical composition inhibits the enzymatic activity of tankyrase (TNKS), inhibits the expression of a beta-catenin target gene and the protein expression of active beta-catenin, stabilizes AXIN2 protein levels, and exhibits anti-cancer activity in a cancer cell line, so that the compound can be used as an anti-cancer agent, in particular as an anti-cancer agent. And elicits synergistic effects in combination therapy with other anti-cancer agents.

The present application relates to a kind of D / L amino acid alternate arrangement anti-hair loss hair growth peptide and its preparation method and application, belong to biological medicine technical field.The amino acid sequence of the polypeptide is as shown in SEQ ID NO:1, is designed by D type and L type amino acid alternate arrangement, significantly enhance the ability of anti-protease degradation, in vitro half-life is ≥48 hours, and activate β-catenin protein expression in hair follicle stem cell.Its preparation method includes: using Rink Amide resin as carrier, using Fmoc solid-phase synthesis method sequentially coupling D / L type amino acid, after cleaving resin by trifluoroacetic acid, by high performance liquid chromatography purification, yield is ≥80%, purity is ≥96%, mass spectrum confirms molecular weight is 956.12Da.The polypeptide can be applied to the preparation of anti-hair loss hair growth cosmetics, drugs and medical devices, effectively solve the problem of low polypeptide stability, insufficient targeting in prior art.

The present invention confirms that when stem cells are phase-changed into a gel (gel) state by mixing a hydrogel in a sol state composed of a polymer capable of sol-gel (gel) phase change with the stem cells, the stem cells can be cultured at a uniform high density in a 3D state. Furthermore, when the stem cells are cultured by the method, the stem cells are stretched by adjusting the hydrogel structure to transduce a physical stimulus to the cells, thereby enabling the activation of integrinin-FAK and catenin-Wnt signaling in the cells, and thus it is confirmed that the efficiency of exosome production is increased and functional components are increased. Furthermore, it is confirmed that in the exosome prepared by the method provided by the invention, miRNA components capable of regulating angiogenesis, tissue regeneration and inflammation are increased. Therefore, the exosome prepared by the method of the present invention can be effectively used as a composition for angiogenesis, tissue regeneration, or anti-inflammation.

This invention relates to peptides that promote hair growth or prevent or inhibit hair loss. The peptides of this invention promote the proliferation of follicular dermal papilla cells (HFDPC) and human pilosebaceous dermal sheath cells (HHORSC), upregulate the expression of β-catenin secondary factor in HFDPC, upregulate the expression of growth factors in HFDPC, and downregulate the expression level of Dickkopf-1 (DKK-1), a protein that causes hair loss.

Pharmaceutical compositions and compounds comprising a phosphorothioated CpG oligodeoxynucleotide linked to a DNA oligonucleotide that is hybridized an RNA aptamer are useful in methods of treating cancer (such as leukemia) and methods of inhibiting DNA methyltransferase. In embodiments, the RNA aptamer binds to an intracellular target such as DNMT1, NF-kB, RUNX1, MYC, MYB, ETS, PAX5, MDM2, F0XM1, PU.l, STAT3, STATS. STAT6, FAD, ATP5B, or beta-catenin.

The present invention relates to techniques for constructing and culturing hair follicle-like organs for use in hair drug screening methods and in the production of hair graft materials. More specifically, in the present invention, hair follicles are isolated from existing skin organoid derived from human induced pluripotent stem cells and cultured on a culture insert coated with collagen and Matrigel to observe the growth and degradation of hair follicles. Transplanting the cultured hair follicles into the skin allows new hair to grow, demonstrating the potential use of the hair follicle organoid as a hair transplant material. According to treatment of hair follicle-like organs with hair loss inducing factors, it is observed that the hair follicle length is shortened, hair papilla cell aggregates are damaged, the expression of WNT3A or beta-catenin is reduced, and the expression of DKK-1 or TGF-beta2 is increased, so that a hair loss simulation model is established. Through observation, the organ is expected to be widely applied, such as a screening method of a hair growth promoter, a hair loss prevention agent, a hair loss alleviator or a hair loss treatment agent, and a screening method of a cosmetic composition for promoting hair growth, preventing hair loss or alleviating hair loss.

This invention relates to peptides with activity that promotes hair growth or prevents or inhibits hair loss. The peptides of this invention promote the proliferation of human follicular dermal papilla cells (HFDPC), activate cell proliferation-related signaling proteins and β-catenin in HFDPC, enhance the expression levels of downstream genes of β-catenin, downregulate the expression level of the hair loss protein DKK-1, increase the expression of keratin in hair follicle outer root sheath cells (HORSC), and upregulate the expression of transcription factors involved in cell activation in germinal stromal cells (GMC).

The present invention relates to peptides having an activity of promoting hair growth or preventing or inhibiting hair loss. The peptides according to the present invention promote proliferation of hair follicle dermal papilla cells (HFDPC) and human hair root sheath cells (HHORSC), upregulate expression of a beta-catenin secondary factor in hair follicle dermal papilla cells (HFDPC), and upregulate expression of a growth factor.

The invention belongs to the technical field of biological medicines, and discloses a deep-sea naphthyridine pyran alkaloid compound, a preparation method thereof and application of the deep-sea naphthyridine pyran alkaloid compound in preparation of medicines for preventing and / or treating bone metabolism diseases, particularly bone metabolism diseases such as bone fracture, osteoporosis, rickets, endocrine bone diseases, osteitis deformans and hereditary bone diseases. The new skeleton compound composed of 2, 7-naphthyridinone and pyranol is found for the first time, can promote mineralization of osteogenesis by targeting beta-catenin protein so as to achieve an obvious effect of promoting fracture repair, has obvious activity of promoting osteoblast mineralization and anti-bone metabolism activity, can be used for preparing an osteoblast activator, and can be used for preparing a bone repair material. And the compound has a good application prospect in the aspect of preparing medicines for preventing and / or treating bone metabolic diseases.

Provided are compounds of the Formula I: or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.

The invention provides a small molecule inhibitor for targeting beta-catenin / BCL9 (Beta-catenin) protein-protein interaction. Specifically, the invention provides a compound or a pharmaceutically acceptable salt thereof, the compound is shown as a formula (I), and each variable is defined in the text.

Provided are compounds of the Formula I:or pharmaceutically acceptable salts thereof, which are useful for the modulation of beta catenin condensates and in the treatment of a variety of conditions or diseases associated therewith.

The present invention relates to a method of treating cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a first peptide, wherein the first peptide comprises a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-33, 52-65, and function-conservative variants thereof. Also provided is a pharmaceutical composition for the treatment of cancer, the pharmaceutical composition comprising: a first peptide, wherein the first peptide comprises a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-33, 52-65, and function-conservative variants thereof.

The invention relates to a peptide capable of promoting hair growth and preventing and inhibiting alopecia and application thereof. The peptide provided by the invention has the following activities: promoting proliferation of hair follicle dermal papilla cells (HFDPC), activating cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhancing the expression level of growth factor-related genes, enhancing the expression level of beta-catenin downstream genes, reducing the expression level of alopecia protein DKK-1, and promoting the growth of the hair follicle dermal papilla cells. Increasing the expression of keratin in hair outer root sheath cells (HORSC), and increasing the expression of transcription factors involved in cell activation in hair growth stromal cells (GMC); and promoting differentiation of hair follicle stem cells (HFSC).

Methods of administering a peptide antagonist of beta-catenin and methods of treating solid tumors by administering a peptide antagonist of beta-catenin are provided.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

The invention provides an application of a Wnt / beta-catenin inhibitor in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biological medicines. And the Wnt / beta-catenin inhibitor is KYA1797K, and the Wnt / beta-catenin inhibitor is KYA1797K According to the application disclosed by the invention, the expression of beta-catenin protein is successfully inhibited through a KYA1797K targeted Wnt / beta-catenin pathway, the cardiac function of a myocardial infarction mouse is remarkably improved, and the left ventricular ejection fraction (EF) and the left ventricular shortening fraction (FS) are remarkably recovered, so that the Wnt / beta-catenin inhibitor KYA1797K has a good treatment effect on myocardial infarction. In addition, a myocardial fibrosis area of a KYA1797K treatment group is obviously reduced, which indicates that the KYA1797K has an anti-myocardial fibrosis effect. The development result further proves the potential application value in myocardial infarction treatment.

The present invention relates to methods and compositions comprising RNAi agents (e.g., double-stranded RNA (dsRNA) agents) that target the beta-catenin (CTNNB1) gene for the treatment of CTNNB1-related disorders, such as cancer, such as hepatocellular carcinoma and colorectal cancer. The invention also relates to RNAi agents (e.g., double-stranded RNA (dsRNA) agents) that target the beta-catenin (CTNNB1) gene in combination with one or more therapeutic and / or therapeutic agents (e.g., immunotherapeutic agents, e.g., one or more immune checkpoint inhibitors, e.g., PD-1 inhibitors (e.g., anti-PD-1 antibodies or antigen binding fragments thereof), PD-L1 inhibitors, CTLA-4 inhibitors; and / or a VEGF inhibitor for use in the treatment of a subject having a CTNNB1-related disorder, such as cancer, such as hepatocellular carcinoma and colorectal cancer.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.

Herein are multivalent antibody binding molecules that activate a Wnt / β-catenin signaling pathway comprising a FZD4 receptor binding domain, an LRP5 co-receptor binding domain, and a VEGF binding domain. Also described herein are nucleic acids and vectors encoding said molecules and methods for their use.